Vensica Medical

Vensica Medical is an Israeli biotechnology company focused on developing innovative urology therapeutics. Founded in 2015, the company operates from Brooklyn, N.Y., and is known for its needle-free, ultrasound-based drug delivery platform. This technology, called Vibe®, is designed to treat urological conditions, primarily overactive bladder (OAB), using botulinum toxin A (Xeomin®). Vensica's approach aims to enhance patient comfort and treatment efficacy by minimizing pain and procedural complexity compared to traditional needle injections.

The company has secured significant funding to support its clinical trials in the U.S. and Europe, with key partnerships, including Merz Therapeutics, which provides clinical development support and exclusive rights for Xeomin® in specific urologic applications. Vensica is committed to advancing localized drug delivery solutions for urological therapies, with plans to expand its technology to address additional bladder conditions in the future.